2 Defensive Dividend Stocks Yielding Over 20%

2 Defensive Dividend Stocks Yielding Over 20%

After the crazy volatility we’ve seen this week – the Dow has been swinging 1,000 points or more in consecutive sessions – it may be time to step back and consider the longer term. Yes, the COVID-19 epidemic will have an economic impact. Hotels and tour companies, manufacturers with China-based supply chains, shipping and trucking companies – all are seeing losses and either implementing or considering layoffs. But does the situation justify a prolonged market slump?Briefly, the answer is no. Yes, there are disruptions now – but in China, the disease’s epicenter and still the country most strongly effected, with a majority of the world’s coronavirus cases, there are signs that the epidemic spread has peaked, and that manufacturers and other businesses are starting to get back to work. Additionally, diagnostic test kits are coming available, vaccine development is proceeding.The upshot is, while increased volatility is almost certainly going to stay...

3 Beaten-Up Penny Oil Stocks Only for the Bold

Just when it looked like things couldn't get any worse for oil stocks, they did. In a big way.Already reeling in February from falling demand in the wake of the novel coronavirus outbreak going global, oil stocks collapsed even further in early March on news that Russia and OPEC began an all-out oil price war. Many oil stocks are now down more than 50% year-to-date. A handful are down 90% or more in 2020.The wipe out plunged many oil stocks into penny stock territory, with the implication being that bankruptcy is a real and likely option for many of these companies over the next few months.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat may not happen. There is a chance that COVID-19, which is spreading like wildfire today, actually starts to slow over the next few months as a coordinated effort from countries and businesses across the world to...

The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus. I-Mab ADR (NASDAQ: IMAB)The Shanghai-based biopharma said Friday it is initiating the development pf TJM2 to treat cytokine storms in severe and critically ill patients caused by COVID-19. TJM2 is a neutralizing antibody against human granulocyte-macrophage colony stimulating factor, an important cytokine that plays a key role in acute and chronic inflammation.The company said it is awaiting FDA acceptance of an investigational new drug application. La Jolla Pharmaceutical Company (NASDAQ: LJPC)La Jolla said Friday that it is providing Giapreza in Italy for compassionate use in patients with septic shock associated with COVID-19. Giapreza was approved by the FDA in 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.It was later approved by the European Commission for treating refractory hypotension in adults with septic...